Evidence map›Paper›PMID 30165580›Full record

Observational studyEuropean heart journal2018

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.

Sanjiv J Shah, Carolyn S P Lam, Sara Svedlund, Antti Saraste, Camilla Hage, Ru-San Tan, Lauren Beussink-Nelson, Ulrika Ljung Faxén, Maria Lagerström Fermer, Malin A Broberg and 2 more

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 365 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
365citing papers in PubMed, 5 pooled it
32.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04128891 phase3withdrawnnot on this mapstarted 2020, after this paper: background citation

PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction

TypeinterventionalSponsorFlinders UniversityRan2020 to 2024Enrolled0ConditionsHeart Failure With Preserved Ejection FractionArmsSacubitril-Valsartan
NCT04395846 active not recruitingnot on this mapstarted 2020, after this paper: background citation

Heart Failure and Preserved Ejection Fraction: Observation of Its Progression and Prognosis (HOPP-BERN)

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2020 to 2029Enrolled350ConditionsHeart Failure With Preserved Ejection Fraction
3 · Its place in the literature

Who cites it

365 citing papers in PubMed, 5 syntheses or guidelines pooled it, 589 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Review
  15. Microvascular dysfunction and heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  16. Article
  17. Chronic Inflammation and Coronary Microvascular Dysfunction.Reviews in cardiovascular medicine · 2026
    Review
  18. Review
  19. Review
  20. Review

305 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Carolyn S P LamNational Heart Centre Singapore, Duke-National University of Singapore, Singapore.
Sara SvedlundDepartment of Clinical Physiology, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
Antti SarasteHeart Center, Turku University Hospital, University of Turku, Turku, Finland.
Camilla HageDepartment of Medicine, Cardiology Unit and Heart and Vascular Theme, Karolinska Institutet, Stockholm, Sweden.
Ru-San TanNational Heart Centre Singapore, Duke-National University of Singapore, Singapore.
Lauren Beussink-NelsonDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ulrika Ljung FaxénDepartment of Medicine, Cardiology Unit and Heart and Vascular Theme, Karolinska Institutet, Stockholm, Sweden.
Maria Lagerström FermerEarly Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden.
Malin A BrobergEarly Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden.
Li-Ming GanEarly Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden.
Lars H LundDepartment of Medicine, Cardiology Unit and Heart and Vascular Theme, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEAstraZeneca (Sweden) · SENorthwestern University · USSahlgrenska University Hospital · SENational University Heart Centre Singapore · SGTurku University Hospital · FIUniversity Medical Center Groningen · NL

Funding

Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and PhenomicsR01HL127028 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD, SHAH, SANJIV J · 2015 to 2018
$6.5M
NHLBI NIH HHS R01 HL127028
6 · The paper itself

Abstract

Aims: To date, clinical evidence of microvascular dysfunction in patients with heart failure (HF) with preserved ejection fraction (HFpEF) has been limited. We aimed to investigate the prevalence of coronary microvascular dysfunction (CMD) and its association with systemic endothelial dysfunction, HF severity, and myocardial dysfunction in a well defined, multi-centre HFpEF population. Methods and results: This prospective multinational multi-centre observational study enrolled patients fulfilling strict criteria for HFpEF according to current guidelines. Those with known unrevascularized macrovascular coronary artery disease (CAD) were excluded. Coronary flow reserve (CFR) was measured with adenosine stress transthoracic Doppler echocardiography. Systemic endothelial function [reactive hyperaemia index (RHI)] was measured by peripheral arterial tonometry. Among 202 patients with HFpEF, 151 [75% (95% confidence interval 69-81%)] had CMD (defined as CFR <2.5). Patients with CMD had a higher prevalence of current or prior smoking (70% vs. 43%; P = 0.0006) and atrial fibrillation (58% vs. 25%; P = 0.004) compared with those without CMD. Worse CFR was associated with higher urinary albumin-to-creatinine ratio (UACR) and NTproBNP, and lower RHI, tricuspid annular plane systolic excursion, and right ventricular (RV) free wall strain after adjustment for age, sex, body mass index, atrial fibrillation, diabetes, revascularized CAD, smoking, left ventricular mass, and study site (P < 0.05 for all associations). Conclusions: PROMIS-HFpEF is the first prospective multi-centre, multinational study to demonstrate a high prevalence of CMD in HFpEF in the absence of unrevascularized macrovascular CAD, and to show its association with systemic endothelial dysfunction (RHI, UACR) as well as markers of HF severity (NTproBNP and RV dysfunction). Microvascular dysfunction may be a promising therapeutic target in HFpEF.

Indexed as

Heart Failure, DiastolicAgedAged, 80 and overCoronary VesselsEchocardiography, DopplerFemaleHumansMaleMicrovesselsMiddle AgedProspective Studies

Identifiers

PMID30165580
PMCPMC6927847
OpenAlexW2889002990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.